HIV positive patient with severe hemophilia A and malignant lymphoma: prophylaxis with recombinant fviii

被引：0
|
作者：
Geierova, V [1 ]
Pohlreichova, V [1 ]
Rittich, S. [1 ]
Benesova, K. [2 ]
Hrachovinova, I., V [1 ]
Cetkovsky, P. [2 ]
Salaj, P. [1 ]
机构：
[1] Inst Hematol & Blood Transfus, Ctr Thrombosis & Hemostasis, Prague 2, Czech Republic
[2] Inst Hematol & Blood Transfus, Clin Dept, Prague 2, Czech Republic
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-MO-583
引用
收藏
页码：516 / 516
页数：1
相关论文
共 50 条
  • [1] Malignant lymphoma in the HIV-positive patient
    Meister, Anne
    Hentrich, Marcus
    Wyen, Christoph
    Huebel, Kai
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 119 - 126
  • [2] Patient with hemophilia a carrier developing FVIII inhibitor after recombinant FVIII therapy
    Bulbul, H.
    Atilla, F. D.
    Unat, A. A.
    Demirci, Z.
    Sahin, F.
    HAEMOPHILIA, 2018, 24 : 80 - 80
  • [3] Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
    Abolghasemi, Hassan
    Panahi, Yunes
    Ahmadinejad, Minoo.
    Toogeh, Gholamreza
    Karimi, Mehran
    Eghbali, Aziz
    Mirbehbahani, Nargess Bigom
    Dehdezi, Bighan Keikhaei
    Badiee, Zahra
    Hoorfar, Hamid
    Eshghi, Peyman
    Maghsoudi, Nader
    Sahebkar, Amirhossein
    Gholami-Fesharaki, Mohammad
    JOURNAL OF PHARMACOPUNCTURE, 2018, 21 (02) : 76 - 81
  • [4] Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A
    Dargaud, Yesim G.
    Klamroth, Robert
    Rusen, Luminita
    Windyga, Jerzy
    Bichler, Johann
    Knaub, Sigurd
    Negrier, Claude
    BLOOD, 2016, 128 (22)
  • [5] Multicenter retrospective and prospective analysis of emicizumab and FVIII prophylaxis in children with severe hemophilia A
    Hassan, Tamer
    Lotfy, Gehan
    Elalfy, Omar
    Amin, Mervat
    Elmasry, Zahraa
    Elhawary, Eslam
    Darwish, Ahmed
    Elalfy, Mohsen
    HAEMOPHILIA, 2024, 30 : 222 - 223
  • [6] Prophylaxis treatment in young severe hemophilia A patients: efficacy, FVIII consumption, trough FVIII levels and therapy compliance
    Biondo, F.
    Santoro, C.
    Baldacci, E.
    Leporace, A.
    Mazzucconi, M. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 928 - 929
  • [7] Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
    Megias Vericat, J. E.
    Marques, R.
    Haya, S.
    Cid, A. R.
    Querol, F.
    Monte, E.
    Garcias Dasi, M.
    Caunedo, P.
    Bosch, P.
    Curats, R.
    Poveda, J. L.
    Bonanad, S.
    HAEMOPHILIA, 2018, 24 : 92 - 93
  • [8] Association of prophylaxis regimen with FVIII and treatment outcomes in Latin America patients with severe hemophilia A
    Perez Bianco, P.
    Berges, A.
    Soto, V.
    Linares, A.
    Krishnan, S.
    Xiong, Y.
    Aguilar, L.
    Gomez, J.
    Arvizu, J.
    Brabata, C.
    HAEMOPHILIA, 2012, 18 : 143 - 143
  • [9] BURKITTS-LYMPHOMA IN A PATIENT WITH SEVERE HEMOPHILIA
    DIEZ, JSJ
    CHILLON, FG
    FERNANDEZ, AC
    CAVERO, JIT
    SAIZ, MLC
    MEDICINA CLINICA, 1986, 87 (02): : 68 - 70
  • [10] Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
    Preblick, Ronald
    Gray, Cori
    Ali, Talaha
    DasMahapatra, Pronabesh
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (09): : 1177 - 1177
12345